Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$4.82
+5.7%
$2.60
$1.98
$4.50
$462.76M1.441.27 million shs129,834 shs
Evotec SE stock logo
EVO
Evotec
$4.27
+3.4%
$3.91
$2.84
$5.64
$1.52B1.66133,197 shs58,849 shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$15.75
+1.9%
$14.27
$10.60
$38.12
$1.66B0.281.20 million shs1.13 million shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$25.46
-3.0%
$26.97
$22.48
$71.71
$1.51B2.96868,811 shs605,445 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
+11.22%+4.83%+12.32%-42.93%-55.34%
Evotec SE stock logo
EVO
Evotec
+0.24%+2.48%-4.62%+20.76%-11.18%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+1.25%+4.11%+5.97%-38.67%-9.81%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+1.16%+3.19%+2.66%-17.51%-39.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Evotec SE stock logo
EVO
Evotec
2.0438 of 5 stars
3.24.00.00.02.00.00.6
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.8471 of 5 stars
4.41.00.00.02.13.30.0
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.2014 of 5 stars
3.52.00.00.02.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Evotec SE stock logo
EVO
Evotec
2.40
Hold$5.9338.95% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.78
Moderate Buy$39.78152.56% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.09
Buy$95.25274.12% Upside

Current Analyst Ratings Breakdown

Latest CERC, EWTX, EVO, and JANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$48.00
5/15/2025
Evotec SE stock logo
EVO
Evotec
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
4/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$41.00
4/24/2025
Evotec SE stock logo
EVO
Evotec
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/21/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.00
4/3/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.00
4/2/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.00
4/2/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.00
(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M69.07N/AN/A$0.22 per share21.91
Evotec SE stock logo
EVO
Evotec
$788.22M1.92$0.03 per share161.08$3.42 per share1.25
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.53 per shareN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$9.34M161.37N/AN/A$7.46 per share3.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Evotec SE stock logo
EVO
Evotec
-$90.82MN/A0.00N/AN/AN/AN/AN/A8/13/2025 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$100.16M-$1.55N/AN/AN/AN/A-26.83%-25.67%8/6/2025 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%8/6/2025 (Estimated)

Latest CERC, EWTX, EVO, and JANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.45-$0.43+$0.02-$0.43N/AN/A
5/8/2025Q1 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Evotec SE stock logo
EVO
Evotec
0.43
2.09
1.99
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
26.35
26.35
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
38.80
38.80

Institutional Ownership

CompanyInstitutional Ownership
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Evotec SE stock logo
EVO
Evotec
5.81%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%

Insider Ownership

CompanyInsider Ownership
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Evotec SE stock logo
EVO
Evotec
1.00%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
23.20%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Evotec SE stock logo
EVO
Evotec
4,200355.11 million350.83 millionNot Optionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.20 million71.86 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3059.18 million37.05 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Evotec stock logo

Evotec NASDAQ:EVO

$4.27 +0.14 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$4.27 0.00 (0.00%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$15.75 +0.30 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$15.75 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$25.46 -0.78 (-2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$25.69 +0.23 (+0.90%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.